OVID Ovid Therapeutics Inc.

4.01
+0.02  (+1%)
Previous Close 3.99
Open 4.05
Price To Book 6.37
Market Cap 191,743,900
Shares 47,816,434
Volume 387,183
Short Ratio
Av. Daily Volume 687,227
Stock charts supplied by TradingView

NewsSee all news

  1. Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

    NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  2. Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

    Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed

  3. Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

    Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged Treatment in

  4. Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

    Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company

  5. Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due early 2020.
OV101 (ROCKET)
Fragile X syndrome
Phase 2 open label data released September 23, 2019.
OV935 ENDYMION
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 data due mid-2020.
OV101 - NEPTUNE
Adolescents with Angelman syndrome
Phase 2 top-line data due 2H 2020.
TAK-935/OV935 (ELEKTRA)
Dravet Syndrome / Lennox-Gastaut Syndrome
Phase 1b/2a data due 1Q 2020.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

Latest News

  1. Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

    NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  2. Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

    Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed

  3. Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

    Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged Treatment in

  4. Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

    Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company

  5. Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  6. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  7. Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

    Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare

  8. Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  9. Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  10. Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today